Skip to content

Replimune Group REPL Restricted Cash

Restricted Cash at other companies

Immunome logo
ImmunomeIMNM
$210K+110%
Erasca, Inc. logo
Erasca, Inc.ERAS
$408K0.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$1.34M-37.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.28M+59.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's restricted cash?
Replimune Group (REPL) reported restricted cash of $1.7M in Q4 2025.
How has Replimune Group's restricted cash changed year-over-year?
Replimune Group's restricted cash increased by 0.2% year-over-year, from $1.7M to $1.7M.
What is the long-term trend for Replimune Group's restricted cash?
Over 4 years (2021 to 2025), Replimune Group's restricted cash has grown at a 1.0% compound annual growth rate (CAGR), from $1.64M to $1.7M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.